ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 330,17
-0,34%
Dow Jones
42 992,21
-0,77%
DAX
19 915,64
-0,22%
Brent Oil
73,47
-0,21%
Bitcoin
93 661,61
0,15%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Inhibikase Therapeutics Inc (IKT)

  7. Inhibikase Therapeutics Inc (IKT) Actualités

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IKT
DateHeureSourceTitreSymboleSociété
06/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IKTInhibikase Therapeutics Inc
05/12/202422h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
05/12/202422h47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IKTInhibikase Therapeutics Inc
03/12/202412h24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202422h49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202422h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
14/11/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
08/11/202422h07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
28/10/202422h26Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
25/10/202423h52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
24/10/202401h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202422h25GlobeNewswire Inc.Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/08/202414h00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:IKTInhibikase Therapeutics Inc
18/06/202423h27Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
17/06/202414h05GlobeNewswire Inc.Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseNASDAQ:IKTInhibikase Therapeutics Inc
05/06/202414h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
04/06/202422h11Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IKTInhibikase Therapeutics Inc
22/05/202414h55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
20/05/202414h01GlobeNewswire Inc.Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionNASDAQ:IKTInhibikase Therapeutics Inc
16/05/202402h00GlobeNewswire Inc.Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202414h45GlobeNewswire Inc.Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202413h56Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IKTInhibikase Therapeutics Inc
09/05/202420h41Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
09/05/202414h00GlobeNewswire Inc.Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
18/04/202422h30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
03/04/202414h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
27/03/202421h15GlobeNewswire Inc.Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/03/202414h30GlobeNewswire Inc.Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersNASDAQ:IKTInhibikase Therapeutics Inc
28/02/202422h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
07/02/202413h55GlobeNewswire Inc.Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT

Dernières Valeurs Consultées

LATK
KEYUSDT
Selfkey
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés